文献速递结核与非结核分枝杆菌

儿童结核感染中利福喷丁与异烟肼药代动力学的遗传与临床预测因素

Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

研究在12例结核感染儿童中于治疗第4周采集90份血浆和41份尿液样本,用NONMEM建立利福喷丁与异烟肼药代动力学模型,并分析ABCB1、SLCO1B1、AADAC和NAT2基因及临床协变量。异烟肼非肾清除率在NAT2快、中、慢乙酰化者中分别为3.52、2.91和2.58 L·h-1;ABCB1突变等位基因携带者利福喷丁生物利用度较低,作者认为可能需更高利福喷丁剂量但须在更大试验中确认。

要点

  • 12例结核感染儿童第4周采集90份血浆和41份尿液样本建立药代模型。
  • 异烟肼非肾清除率在NAT2快、中、慢乙酰化者中分别为3.52、2.91和2.58 L·h-1。
  • ABCB1突变等位基因携带者利福喷丁生物利用度较低,作者认为可能需更高剂量但须更大试验确认。

核心结论

  • ABCB1突变等位基因携带者可能需要更高利福喷丁剂量,但须在更大试验中确认。
  • 食物不影响异烟肼总体暴露,仅延迟吸收时间。

研究设计与样本

  • 在12例结核感染儿童中使用NONMEM建立利福喷丁与异烟肼药代动力学模型。
  • 于治疗第4周采集90份血浆和41份尿液样本,用经验证的HPLC-UV法测定药物浓度。
  • 用MassARRAY® SNP基因分型检测ABCB1、SLCO1B1、AADAC和NAT2遗传因素,并分析临床相关协变量。

主要发现

  • 异烟肼采用二室模型、利福喷丁采用一室模型加转运室吸收和一阶消除能最好描述血浆和尿液数据。
  • 异烟肼非肾清除率估计值(相对标准误,RSE)在NAT2快乙酰化者为3.52 L·h-1(23.1%)、中间乙酰化者为2.91 L·h-1(19.6%)、慢乙酰化者为2.58 L·h-1(20.0%)。
  • 相当比例的原形异烟肼经肾清除(2.7 L·h-1;8.0%),原形利福喷丁主要经非肾途径清除(0.681 L·h-1;3.6%)。
  • ABCB1突变等位基因携带者利福喷丁生物利用度较低,食物延长异烟肼的平均转运时间。

关键数值与推荐

  • 异烟肼非肾清除率在NAT2快、中间、慢乙酰化者分别为3.52 L·h-1(23.1%)、2.91 L·h-1(19.6%)、2.58 L·h-1(20.0%)。
  • 原形异烟肼肾清除率为2.7 L·h-1(8.0%),原形利福喷丁非肾清除率为0.681 L·h-1(3.6%)。

临床怎么用

  • ABCB1突变等位基因携带者可能需要更高利福喷丁剂量,但须在更大试验中确认(作者结论)。
  • 食物不影响异烟肼总体暴露,仅延迟吸收时间(作者结论)。

局限性

  • 样本量为12例儿童。
  • 作者指出ABCB1突变等位基因携带者可能需要更高利福喷丁剂量,但必须在更大试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Twelve weekly doses of rifapentine and isoniazid (3HP regimen) are recommended for TB preventive therapy in children with TB infection. However, they present with variability in the pharmacokinetic profiles. The current study aimed to develop a pharmacokinetic model of rifapentine and isoniazid in 12 children with TB infection using NONMEM. METHODS: Ninety plasma and 41 urine samples were collected at Week 4 of treatment. Drug concentrations were measured using a validated HPLC-UV method. MassARRAY® SNP genotyping was used to investigate genetic factors, including P-glycoprotein (ABCB1), solute carrier organic anion transporter B1 (SLCO1B1), arylacetamide deacetylase (AADAC) and N-acetyl transferase (NAT2). Clinically relevant covariates were also analysed. RESULTS: A two-compartment model for isoniazid and a one-compartment model for rifapentine with transit compartment absorption and first-order elimination were the best models for describing plasma and urine data. The estimated (relative standard error, RSE) of isoniazid non-renal clearance was 3.52 L·h-1 (23.1%), 2.91 L·h-1 (19.6%), and 2.58 L·h-1 (20.0%) in NAT2 rapid, intermediate and slow acetylators. A significant proportion of the unchanged isoniazid was cleared renally (2.7 L·h-1; 8.0%), while the unchanged rifapentine was cleared primarily through non-renal routes (0.681 L·h-1; 3.6%). Participants with the ABCB1 mutant allele had lower bioavailability of rifapentine, while food prolonged the mean transit time of isoniazid. CONCLUSIONS: ABCB1 mutant allele carriers may require higher rifapentine doses; however, this must be confirmed in larger trials. Food did not affect overall exposure to isoniazid and only delayed absorption time.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Phaisal W, Albitar O, Chariyavilaskul P, et al. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection. J Antimicrob Chemother. 2024. PMID: 38661209. doi:10.1093/jac/dkae059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。